Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Enterprise Value (2021 - 2026)

Pyxis Oncology (PYXS) has 6 years of Enterprise Value data on record, last reported at -$16.9 million in Q4 2025.

  • On a quarterly basis, Enterprise Value rose 19.34% to -$16.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$16.9 million, a 19.34% increase, with the full-year FY2025 number at -$16.9 million, up 19.34% from a year prior.
  • Enterprise Value reached -$16.9 million in Q4 2025 per PYXS's latest filing, down from -$10.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for PYXS hit a ceiling of -$10.4 million in Q3 2025 and a floor of -$276.2 million in Q4 2021.
  • A 5-year average of -$116.0 million and a median of -$126.1 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 1086.88% in 2021, then skyrocketed 89.83% in 2024.
  • Tracing PYXS's Enterprise Value over 5 years: stood at -$276.2 million in 2021, then surged by 34.55% to -$180.8 million in 2022, then soared by 34.0% to -$119.3 million in 2023, then soared by 82.44% to -$20.9 million in 2024, then rose by 19.34% to -$16.9 million in 2025.
  • Business Quant data shows Enterprise Value for PYXS at -$16.9 million in Q4 2025, -$10.4 million in Q3 2025, and -$88.9 million in Q2 2025.